$AKTS News

Aktis Oncology: Padcev Is Building The Market It Wants

Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519

Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Aktis Oncology to Present at Upcoming September Investor Conferences

Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says

Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate

JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40

Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Aktis Oncology: Mini-Proteins With A Targeted Punch

HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors